SCYNEXIS, Inc. (0L49.L)
LSE · USD
$3.84 (-1.16%) as of
Key statistics
- EPS (TTM)
- -1.2040
- 52-week range
- 1.3488 – 4.0200
- Beta
- 1.06
- Revenue (TTM)
- 19.22M
- Profit margin
- -53.26%
- Volume
- 33.00
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
- Headquarters
- Jersey City, NJ, United States
- Employees
- 18
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.